Participants in the study will receive either rituximab or a placebo through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will also involve the use of other medications such as paracetamol, clemastine, chlorphenamine maleate, methylprednisolone, and sodium chloride as part of the treatment process. These medications are commonly used to manage symptoms and support the treatment process. The study will monitor the heart’s pumping ability, known as the left ventricular ejection fraction, using a special imaging technique called CMR (Cardiac Magnetic Resonance) six months after the heart attack.

Throughout the study, additional assessments will be conducted to evaluate the size of the heart attack, the presence of swelling in the heart tissue, and any potential side effects related to the treatment. These assessments will help researchers understand the impact of rituximab on heart recovery after a STEMI. The study aims to provide valuable insights into improving treatment options for patients who have suffered from this type of heart attack.